Advertisement

Latest News

RGX-314 Gene Therapy for nAMD Well-Tolerated in Phase 1/2a Study

49 minutes ago

A single administration of ABBV-RGX-314 was generally well tolerated, with little to no supplemental anti-VEGF injections required in most patients at two years.

Diabetes Dialogue: All Things AID at ATTD 2024

1 hour ago

In this episode, all things AID from the 17th annual ATTD, including updates from Insulet Corporation and Omnipod, study data from the Control IQ algorithm, the SMASH study, and a peak into the future with the Neural Network AID algorithm.

Short-Term Biofeedback Therapies Lead to Alleviation of Certain Long COVID Symptoms

1 hour ago

The investigators seek to replicate the data in a future randomized control trial, and they hope to compare biofeedback to different therapies such as pulmonary rehabilitation.

Appropriate Guidance for CRC Screening Age, Role of Advocacy Organizations

2 hours ago

In part 5 of our 5-part discussion, experts discuss their perspective on appropriate guidance for screening age and the future of CRC advocacy.

Navigating Patient Histories, Risk Factor Conversations in CRC Screening

2 hours ago

In part 4 of our 5-part discussion, experts discuss how to navigate conversations about risk factors and symptoms surrounding CRC.

Advertisement
Advertisement